PRESS RELEASECollaboration and Licensing Agreement • March 11th, 2024
Contract Type FiledMarch 11th, 2024• Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophrenia